Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Further positive results reported from phase Ib trial of Cancer Vac immunotherapy

July 23, 2003

Early completion anticipated for pivotal R-1549 trial

July 21, 2003

MEDI-507 proven effective in a murine model of adult T-cell leukemia

July 15, 2003

MDX-010 combined with tumor vaccines in metastatic melanoma

July 14, 2003

Multikine may enhance success of radiation and chemotherapy in H&N cancer

July 11, 2003

HuMax-CD20 effective in depleting B-cells in primate study

July 10, 2003

Alemtuzumab reported to increase clinical response and remission in refractory CLL

July 8, 2003

Treatment begins in INGN-225 phase I/II study

July 7, 2003

Phase II trial to evaluate Pentrix in prostate cancer

July 4, 2003

Antisoma initiates enrollment in phase I study of R-1550 in breast cancer

July 4, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...